Novartis AG (NVS)
Pre-market:
| Previous close | 96.97 |
| Open | 97.47 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's range | 96.72 - 97.64 |
| 52-week range | 79.98 - 105.61 |
| Volume | |
| Avg. volume | 1,525,017 |
| Market cap | 199.76B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 25.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.50 (3.61%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | N/A |
- PR Newswire
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1. Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]). In clinical trial
- Globe Newswire
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth Mid-term sales guidance upgrade to 5% CAGR (2022-27), with core operating income margin of ~40%+ by 2027, driven by continued strong momentum of key growth drivers Confidence to grow mid-single digit longer-term based on the foundational strength of de-risked existing brands and pipeline assets Focused st
- GlobeNewswire
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-negative disease New 48-week efficacy and safety data from the Phase III APPLY-PNH trial of investigational oral monotherapy iptacopan in anti-C5-treated adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia Nearly 4 year follow-up efficacy and safety results from end of stud
